Quick Answer
Evommune, Inc. reported Stockholders Equity of $205.57 million for the year ending 2025.
- Evommune, Inc. showed an increase of +242.5% in Stockholders Equity from 2024 to 2025.
- This data is from Evommune, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: -$107.03 million | Q3 2024: -$122.53 million | Q2 2025: -$171.23 million | Q3 2025: -$183.14 million.
- Over the full 3 years of available data (2023 to 2025), Evommune, Inc.'s Stockholders Equity has grown by 364.5%.
- Historical annual values: Fiscal year 2025: $205.57 million | Fiscal year 2024: -$144.24 million | Fiscal year 2023: -$77.71 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: